Results 21 to 30 of about 277,119 (298)
Cancer Cell, 2009 Mst1 and Mst2 are key components of the Hippo tumor suppressor pathway. In this issue, Zhou et al. (2009) reported that Mst1/2 ablation leads to hepatocellular carcinomas. Unexpectedly, Mst1/2 may activate another kinase besides Lats1 and Lats2 to phosphorylate YAP, and the role of Mst1/2 in YAP regulation is cell type dependent.
Kun-Liang Guan, Qun-Ying Lei, Bin Zhao
openaire +3 more sources
CXCR2 inhibition enables NASH-HCC immunotherapy
Gut, 2022 Objective Hepatocellular carcinoma (HCC) is increasingly associated with non-alcoholic steatohepatitis (NASH). HCC immunotherapy offers great promise; however, recent data suggests NASH-HCC may be less sensitive to conventional immune checkpoint ...
J. Leslie +45 more
semanticscholar +1 more source
Emerging immunotherapy for HCC: A guide for hepatologists
Hepatology, 2022 HCC is one of the most common cancers worldwide, and the third leading cause of cancer‐related death globally. HCC comprises nearly 90% of all cases of primary liver cancer.
F. Foerster +3 more
semanticscholar +1 more source
Hypoxia‐driven immunosuppression by Treg and type‐2 conventional dendritic cells in HCC
Hepatology, 2022 Hypoxia is one of the central players in shaping the immune context of the tumor microenvironment (TME). However, the complex interplay between immune cell infiltrates within the hypoxic TME of HCC remains to be elucidated.
Sheena Suthen +29 more
semanticscholar +1 more source
Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC [PDF]
Canadian Journal of Gastroenterology and Hepatology, 2021 Hepatocellular carcinoma (HCC) is one of the primary types of cancer that claims many lives worldwide, and its incidence continues to increase. Conventional therapies against liver cancer are inadequate, and the pathogenesis of HCC remains unclear. Thus, not only are more effective therapies to treat HCC required but also identification of the key ...
Yulong Wei +3 more
openaire +3 more sources
Current Hepatology Reports, 2020 Hepatocellular carcinoma (HCC) is a leading cause of cancer related mortality in the world and it has limited treatment options. Understanding the molecular drivers of HCC is important to develop novel biomarkers and therapeutics.HCC arises in a complex background of chronic hepatitis, fibrosis and liver regeneration which lead to genomic changes. Here,
Nia Adeniji, Renumathy Dhanasekaran
openaire +4 more sources
Risk factors for HCC in contemporary cohorts of patients with cirrhosis
Hepatology, 2022 Background and Aims: Etiological risk factors for cirrhosis have changed in the last decade. It remains unclear to what extent these trends in cirrhosis risk factors have changed HCC risk.
F. Kanwal +12 more
semanticscholar +1 more source
Therapeutic efficacy of FASN inhibition in preclinical models of HCC
Hepatology, 2022 Aberrant activation of fatty acid synthase (FASN) is a major metabolic event during the development of HCC. We evaluated the therapeutic efficacy of TVB3664, a FASN inhibitor, either alone or in combination, for HCC treatment.
Haichuan Wang +13 more
semanticscholar +1 more source
Hepatology, 2022 HCV cure reduces but does not eliminate the risk of HCC. HCC surveillance is recommended in populations where the incidence exceeds 1.5% per year. In cirrhosis, HCC surveillance should continue after HCV cure, although it is uncertain if this should be ...
Ian Lockart +4 more
semanticscholar +1 more source
Cell Death and Disease, 2021 Metabolic reprogramming is a new hallmark of cancer but it remains poorly defined in hepatocellular carcinogenesis (HCC). The fatty acid receptor CD36 is associated with both lipid and glucose metabolism in the liver.
Xiaoqing Luo +11 more
semanticscholar +1 more source